iNtRON Biotechnology Inc (048530) - Total Liabilities
Based on the latest financial reports, iNtRON Biotechnology Inc (048530) has total liabilities worth ₩4.73 Billion KRW (≈ $3.20 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
iNtRON Biotechnology Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how iNtRON Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. See 048530 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
iNtRON Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of iNtRON Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Osteonic Co. Ltd
KQ:226400
|
Korea | ₩32.25 Billion |
|
CBAK ENERGY TECH. NEW
F:B6JA
|
Germany | €316.70 Million |
|
Borgestad A
OL:BOR
|
Norway | Nkr663.94 Million |
|
Farmsco
KO:036580
|
Korea | ₩851.51 Billion |
|
CALIX Ltd
AU:CXL
|
Australia | AU$26.33 Million |
|
Norcod As
OL:NCOD
|
Norway | Nkr335.97 Million |
|
Air T Inc
NASDAQ:AIRT
|
USA | $375.87 Million |
|
Yenher Holdings Bhd
KLSE:5300
|
Malaysia | RM42.25 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down iNtRON Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see iNtRON Biotechnology Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how iNtRON Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for iNtRON Biotechnology Inc (2012–2024)
The table below shows the annual total liabilities of iNtRON Biotechnology Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩2.60 Billion ≈ $1.76 Million |
+38.37% |
| 2023-12-31 | ₩1.88 Billion ≈ $1.27 Million |
-94.59% |
| 2022-12-31 | ₩34.78 Billion ≈ $23.57 Million |
-33.14% |
| 2021-12-31 | ₩52.02 Billion ≈ $35.25 Million |
+243.19% |
| 2020-12-31 | ₩15.16 Billion ≈ $10.27 Million |
-37.03% |
| 2019-12-31 | ₩24.07 Billion ≈ $16.31 Million |
+53.26% |
| 2018-12-31 | ₩15.70 Billion ≈ $10.64 Million |
+2.07% |
| 2017-12-31 | ₩15.38 Billion ≈ $10.43 Million |
+47.13% |
| 2016-12-31 | ₩10.46 Billion ≈ $7.09 Million |
+76.39% |
| 2015-12-31 | ₩5.93 Billion ≈ $4.02 Million |
-23.17% |
| 2012-12-31 | ₩7.72 Billion ≈ $5.23 Million |
-- |
About iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.